What is it about?
"Pain is an important subjective adverse event of photoimmunotherapy (conditionally approved in Japan in January 2021 for the treatment of unresectable locally advanced or locally recurrent head and neck cancer that cannot be treated with CRT or other standard therapies)."
Featured Image
Photo by Natanael Melchor on Unsplash
Why is it important?
Pain is an important adverse event in photoimmunotherapy, but its details have not been clarified. The reason is that although this is the first therapy approved in Japan in the world, the number of patients receiving this therapy is not large due to the narrow range of indications. This makes it difficult to accumulate cases and to analyze them to understand their pain. We report the results of our analysis in this paper.
Perspectives
Pain occurs immediately after irradiation and improves over the next few days. Because of the importance of preoperative pain management, head and neck surgeons must collaborate with palliative doctors, nurses, pharmacists, and other medical staff in advance.
Shinya Suzuki
National Cancer Center Hospital East
Read the Original
This page is a summary of: A Case Series on Pain Accompanying Photoimmunotherapy for Head and Neck Cancer, Healthcare, March 2023, MDPI AG,
DOI: 10.3390/healthcare11060924.
You can read the full text:
Contributors
The following have contributed to this page
